财经频道更多独家策划、专家专栏，免费查阅>> 格隆汇12月23日丨辽宁成大(600739.SH)公布，公司于2025年12月19日在全国银行间市场发行规模为7亿 元人民币的辽宁成大股份有限公司2025年度第一期中期票据，募集资金已于2025年12月22日全额到账， 募集资金主要用于偿还公司存量有息债务。票面年利率为3.00%，期限为三年，到期兑付日为2028-12- 22。 责任编辑：钟离 ...

一、同意公司向专业投资者公开发行面值总额不超过20亿元公司债券的注册申请。 二、本次发行公司债券应严格按照报送上海证券交易所的募集说明书进行。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600739 证券简称：辽宁成大 公告编号：2025－085 辽宁成大股份有限公司 关于向专业投资者公开发行公司债券获得中国证监会同意注册批复的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 辽宁成大股份有限公司（以下简称"公司"）收到中国证券监督管理委员会出具的《关于同意辽宁成大股 份有限公司向专业投资者公开发行公司债券注册的批复》（证监许可[2025]2765号），批复内容如下： 三、本批复自同意注册之日起24个月内有效，公司在注册有效期内可以分期发行公司债券。 四、自同意注册之日起至本次公司债券发行结束前，公司如发生重大事项，应及时报告并按有关规定处 理。 公司将按照相关法律、法规和上述批复文件的要求，在公司股东会的授权范围内办理本次发行公司债券 的相关事宜，并及时履行相关信息披露义务。 特此公告。 辽宁成大股份有 ...

截至2025年12月18日收盘，辽宁成大（600739）报收于11.34元，较前一交易日下跌1.05%，最新总市值 为173.47亿元。该股当日开盘11.41元，最高11.44元，最低11.29元，成交额达1.18亿元，换手率为 0.68%。 《辽宁成大股份有限公司关于向专业投资者公开发行公司债券获得中国证监会同意注册批复的公 告》 近日，辽宁成大股份有限公司发布公告称，公司收到中国证券监督管理委员会批复，同意其向专业投资 者公开发行面值总额不超过20亿元的公司债券。本次发行应严格按照报送上海证券交易所的募集说明书 进行。批复自同意注册之日起24个月内有效，公司可在注册有效期内分期发行。期间如发生重大事项， 需及时报告。公司将依法合规办理发行事宜并履行信息披露义务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 最新公告列表 ...

证券代码：600739 证券简称：辽宁成大 公告编号：2025－085 三、本批复自同意注册之日起 24 个月内有效，公司在注册有效期内可以分期 发行公司债券。 四、自同意注册之日起至本次公司债券发行结束前，公司如发生重大事项， 应及时报告并按有关规定处理。 公司将按照相关法律、法规和上述批复文件的要求，在公司股东会的授权范 围内办理本次发行公司债券的相关事宜，并及时履行相关信息披露义务。 特此公告。 关于向专业投资者公开发行公司债券获得中国证监会 同意注册批复的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 辽宁成大股份有限公司（以下简称"公司"）收到中国证券监督管理委员会出 具的《关于同意辽宁成大股份有限公司向专业投资者公开发行公司债券注册的批 复》（证监许可[2025]2765 号），批复内容如下： 一、同意公司向专业投资者公开发行面值总额不超过 20 亿元公司债券的注册 申请。 二、本次发行公司债券应严格按照报送上海证券交易所的募集说明书进行。 辽宁成大股份有限公司 辽宁成大股份有限公司董事会 2025 年 12 ...

Core Viewpoint - The company has received approval from the China Securities Regulatory Commission to publicly issue corporate bonds with a total face value of up to 2 billion yuan [1] Group 1 - The approval allows the company to issue bonds to professional investors [1] - The registered application for the bond issuance is valid for 24 months from the date of approval [1] - The company can issue the bonds in multiple tranches during the validity period [1]

格隆汇12月18日丨辽宁成大(600739.SH)公布，公司收到中国证券监督管理委员会出具的《关于同意辽 宁成大股份有限公司向专业投资者公开发行公司债券注册的批复》（证监许可[2025]2765号），批复内 容如下： 一、同意公司向专业投资者公开发行面值总额不超过20亿元公司债券的注册申请。二、本次发行公司债 券应严格按照报送上海证券交易所的募集说明书进行。三、本批复自同意注册之日起24个月内有效，公 司在注册有效期内可以分期发行公司债券。四、自同意注册之日起至本次公司债券发行结束前，公司如 发生重大事项，应及时报告并按有关规定处理。 ...

智通财经APP讯，辽宁成大(600739.SH)发布公告，公司收到中国证券监督管理委员会出具的《关于同 意辽宁成大股份有限公司向专业投资者公开发行公司债券注册的批复》(证监许可[2025]2765号)，同意 公司向专业投资者公开发行面值总额不超过20亿元公司债券的注册申请。 ...

Core Viewpoint - The biopharmaceutical sector experienced a rise of 0.76% on December 17, with ST Weiming leading the gains. The Shanghai Composite Index closed at 3870.28, up 1.19%, while the Shenzhen Component Index closed at 13224.51, up 2.4% [1]. Group 1: Stock Performance - ST Weiming (002581) closed at 7.49, with a gain of 5.05% and a trading volume of 58,400 shares, amounting to a transaction value of 43.46 million yuan [1]. - Wendi Pharmaceutical (688488) closed at 14.59, up 4.36%, with a trading volume of 56,400 shares and a transaction value of 80.52 million yuan [1]. - Kanghua Biological (300841) closed at 75.75, increasing by 2.98%, with a trading volume of 13,700 shares and a transaction value of 102 million yuan [1]. - Wan Ze Co., Ltd. (000534) closed at 23.31, up 2.24%, with a trading volume of 226,800 shares and a transaction value of 519 million yuan [1]. - Other notable stocks include Kang Le Wei Shi (920575) at 10.28 (+1.88%), Gan Li Pharmaceutical (603087) at 66.80 (+1.71%), and Anke Biological (300009) at 9.67 (+1.58%) [1]. Group 2: Capital Flow - The biopharmaceutical sector saw a net outflow of 344 million yuan from institutional investors, while retail investors experienced a net inflow of 441 million yuan [2]. - The capital flow for ST Weiming showed a net inflow of 14.06 million yuan from institutional investors, while retail investors had a net outflow of 645.75 million yuan [3]. - Kanghua Biological had a net inflow of 13.85 million yuan from institutional investors, with retail investors also experiencing a net outflow of 625.92 million yuan [3].

Core Viewpoint - Liaoning Chengda is focusing on clearing development obstacles to unleash its innovative potential, as stated by Chairman Xu Biao in a recent interview [3][4]. Financial Performance - In the first three quarters of this year, the net profit attributable to shareholders after deducting non-recurring gains and losses increased by 92.20% year-on-year, total assets grew by 2.79% compared to the beginning of the year, and the debt-to-asset ratio decreased by 1.98 percentage points [3]. - As of the end of September, the proportion of long-term loans in total liabilities increased to 14.91%, up by 7.87 percentage points from the beginning of the year, while the proportion of short-term loans decreased to 32.32%, down by 5.19 percentage points [4]. Governance and Shareholder Support - The board restructuring at the beginning of the year was not merely a change in controlling shareholders but a consensus among various shareholders, with Guangdong Min Investment holding approximately 16% of the shares [4]. - The new board and management team include professionals with risk control and investment banking backgrounds, providing solid support for the company's sustainable development [4]. Strategic Focus and Business Optimization - The company has decided to long-term suspend operations at its subsidiary Baoming Mining and will not make significant cash investments in it, focusing instead on attracting strategic investors [6]. - The company aims to improve profitability by reducing weaker business segments while continuing to invest in core industries, particularly in biopharmaceuticals [7]. Investment in Core Industries - Chengda Biopharmaceutical, a core subsidiary, is a focus area for resource integration to enhance research and market positioning [7]. - The company plans to leverage its financial strength to cultivate a second growth curve in innovative vaccines and therapeutic drugs [7][8]. Future Development Plans - Liaoning Chengda has defined its positioning as a "technology industry group based on stable financial investments," while also planning to develop new-generation information technology [9]. - A strategic investment team has been established to explore high-value technology sectors, with plans for mergers and acquisitions to strengthen industry foundations when market conditions are favorable [9].

Core Insights - The company reported a 92.20% year-on-year increase in net profit attributable to shareholders after deducting non-recurring items for the first three quarters of the year, alongside a 2.79% growth in total assets and a 1.98 percentage point decrease in the debt-to-asset ratio [2][3] Governance and Shareholder Support - The board restructuring at the beginning of the year was not merely a change in controlling shareholders but a consolidation of consensus among various shareholders, with Guangdong Min Investment holding approximately 16% of the company [3] - The new board and management team, appointed by Guangdong Min Investment, includes professionals with backgrounds in risk control and investment banking, providing solid support for sustainable development [3] Financial Strategy and Debt Management - The company is committed to reducing leverage, with long-term borrowings now accounting for 14.91% of total liabilities, an increase of 7.87 percentage points since the beginning of the year, while short-term borrowings have decreased to 32.32%, down 5.19 percentage points [3][4] - In November, the company issued its first exchangeable corporate bonds worth 1.8 billion, with a three-year term and a coupon rate of 0.01% [4] Strategic Focus and Operational Efficiency - The decision to suspend operations at its subsidiary Baoming Mining is part of a strategy to focus on core business areas and improve operational efficiency [5] - The company aims to enhance profitability by reducing weaker business segments while continuing to invest in core industries, particularly in biopharmaceuticals [6] Core Business Development - Chengda Biopharmaceuticals, a key subsidiary, is a focus area for resource integration and innovation, with plans to expand into innovative vaccines and therapeutic drugs [7] - The company is leveraging its financial strength to support Chengda Biopharmaceuticals in developing a second growth curve [7] Future Growth and Investment Strategy - The company has positioned itself as a technology industry group based on stable financial investments, with plans to explore new generation information technology as a second growth curve [8] - A strategic investment team has been established to focus on high-value technology sectors, with plans for gradual market entry and resource accumulation [8] Confidence in Performance Recovery - The company expresses strong confidence in its future performance recovery, anticipating that initial investments and strategies will translate into improved operational results over time [9]